SCIENTIFIC PROGRAM

6:45 a.m.  Young Member Mentor Lecture  Key Note Speaker: Dr. William Mieler
The 8 minutes allotted time for each presentation includes time for discussion and audience polling.

THURSDAY, March 10, 2011

Session I: Diabetes I

Chair: Anat Loewenstein  Moderator: Thomas Friberg

7:30 a.m.
Visual Outcomes and Risk Factors in Diabetic Patients at the Joslin Diabetes Center  Lloyd Paul Aiello

7:38 a.m.
Blood pressure control for diabetic retinopathy: A Cochrane systematic review  Robert Frank

7:46 a.m.
Comparison of Multiple Stereoscopic and Monoscopic Digital Image Formats to Film for Diabetic Macular Edema Evaluation  Helen Li

7:54 a.m.
The Clinical Significance of Outer Retinal Layer Disruption in Diabetic Retinopathy  Ayala Pollack

8:02 a.m.
Ranibizumab for Diabetic Macular Edema (DME): 24-Month Safety and Efficacy Results of RISE, a Phase III Randomized Controlled Trial  Dennis Marcus

8:10 a.m.
Intravitreal bevacizumab for diabetic macular edema: 2 year results of the BOLT study  Philip Hykin

8:18 a.m.
Factors Associated with Changes in Visual Acuity and OCT Thickness at One Year after Ranibizumab Treatment for Diabetic Macular Edema  Judy Kim

8:26 a.m.
Effect of Pegaptanib on retinal capillary ischemia as measured by Optos wide angle angiography  Thomas Friberg

8:34 a.m.
A long term outcome of vitrectomy for diabetic macular edema  Shoji Kishi

8:42 a.m.
In Vivo Laser-Tissue Interactions in Central Involving Diabetic Macular Edema Treated with Subthreshold Micropulse Diode Laser  Edoardo Midena
8:50 a.m.
Subthreshold Laser Treatment of Macular Edema in Patients with Diabetes  Anat Loewenstein

Session II: AMD I

Chair: Cynthia Toth                          Moderator: Philip Rosenfeld

9:00 a.m.
Risk Assessment Model for Advanced Age-Related Macular Degeneration  Michael Klein

9:08 a.m.
Biomarkers of oxidative stress and genetic variants in age-related macular degeneration  Milam Brantley

9:16 a.m.
Gene-gene interaction in age-related macular degeneration  Peter Francis

9:24 a.m.
Genomics of Reticular Pseudodrusen in Age Related Macular Degeneration  Anita Agarwal

9:32 a.m.
Quality of life measures in geographic atrophy from AMD  Janet Sunness

9:40 a.m.
Is Primary Multifocal Geographic Atrophy in AMD a form of Reticular Macular Disease?  Theodore Smith

9:48 a.m.
Treatment of Geographic Atrophy by the Topical Administration of OT-551: Results and Development of Outcome Measures  Wai Wong

9:56 a.m.
Near-infrared autofluorescence pattern in early stages of age-related macular degeneration  Maurizio Parodi

10:04 a.m.
Quantitative and Qualitative Assessment of the Macula with SDOCT in Eyes with Intermediate AMD  Cynthia Toth

10:20 a.m. *BREAK*

Session III: Vein Occlusions/Macular Structure&Function

Chair: Vas Sadda                          Moderator: Richard Spaide

10:04 a.m.
A Novel Algorithm for Quantitative Imaging of Retinal Pigment Epithelial Deformations using Spectral Domain Optical Coherence Tomography  Philip J. Rosenfeld
10:40 a.m.
Long-term outcome of central retinal vein occlusion presenting with perivenular whitening Martine Mauget-Faysse

10:48 a.m.
Safety and efficacy outcomes of open-label ranibizumab in retinal vein occlusion: HORIZON extension study Jeffrey Heier

10:56 a.m.
Duration of Macular Edema Influences Clinical Outcomes in Patients with Retinal Vein Occlusion Following Treatment With Dexamethasone Intravitreal Implant Tien Wong

11:04 a.m.
RAVO-Study: Combined treatment of macular edema following central retinal vein occlusion with intravitreal 0.5mg Ranibizumab and isovolemic hemodilution Siegfried Priglinger

11:12 a.m.
Structure-Function Correlation of the Human Central Retina Hendrik Scholl

11:20 a.m.
Analysis of retinal photoreceptor layer in resolved central serous chorioretinopathy by adaptive optics scanning laser ophthalmoscopy Nagahisa Yoshimura

11:28 a.m.
SDOCT Localization of Lamellar Macular Hole Schisis H. McDonald

11:36 a.m.
SDOCT Findings in Solar Maculopathy John Loewenstein

11:44 a.m.
Macular morphological changes that correlate with visual outcome in eyes with surgically closed macular hole: Correlation between Visual Acuity and Inner Macular Volume. Susanna Park

11:52 a.m.
Macular Complications of Tilted Disc Syndrome Salomon Cohen

12:00 p.m.
Structural and Functional Correlation in Sickle Cell Retinopathy Using Microperimetry Testing and SDOCT Imaging Jennifer Lim

12:08 p.m.
Choroidal Thickness Variation in the Posterior Pole of Normal Eyes as Assessed by Optical Coherence Tomography Srini Sadda

12:16 p.m.
Treatment of Chronic Central Serous Chorioretinopathy with Topical Ketotifen Fumarate Jason Slakter

12:24 p.m.
Choroidal Thickness and Visual Acuity in Highly Myopic Eyes Richard Spaide
12:32 p.m.  Presentation of the J. Donald M. Gass Medal  
Recipient: Janet Sunness  
Presenter: Morton Goldberg

12:40 p.m.  Presentation of Green Lecture and Award  
Recipient: David Zacks  
Presenter: Joan Miller

1:04 p.m.  Session Ends

FRIDAY, March 11, 2011

Business Meeting

7:00 a.m.  Macula Society Members Only

Session IV:  AMD II

Chair: David Boyer  
Moderator: R.Olk

7:30 a.m.
Age-Related Macular Degeneration Risk Alleles and Response to Treatment with anti-VEGF Agents  
James Folk

7:38 a.m.
Early Detection Of Exudative Age-related Macular Degeneration With A Home-based Preferential Hyperacuity Perimeter  
Daniel Roth

7:46 a.m.
Hyperacuity perimetry in the detection of onset of neovascular AMD  
Usha Chakravarthy

7:54 a.m.
Potential New Non-Invasive Approach for Visualizing Choroidal Neovascularization  
Neil Bressler

8:02 a.m.
Gabriel Coscas

8:10a.m.
Ranibizumab-induced reduction in the total area of predominantly classic choroidal neovascularization in patients with age-related macular degeneration  
Karl Csaky

8:18 a.m.
Association between restoration of photoreceptor integrity and visual outcome after anti-VEGF treatment in exudative age-related macular degeneration  
Hyoung Jun Koh
8:26 a.m.
**Correlation of retinal morphology and function under anti-VEGF therapy in age-related macular degeneration (AMD)** Ursula Schmidt-Erfurth

8:34 a.m.
**12-month treatment with intravitreal ranibizumab for wet AMD in a “real world” clinical setting** Paolo Lanzetta

8:42 a.m.
**Treatment of Asymptomatic Fluid in the Second Eye of Patients with Neovascular Age-related Macular Degeneration after Detection with Spectral Domain OCT** Lucian Del Priore

8:50 a.m.
**Macular thickness by TD-OCT after the injection of Ranibizumab or Bevacizumab for the treatment of choroidal neovascular membrane associated with age related macular degeneration.** Francisco Rodriguez

8:58 a.m.
**Response to Bevacizumab Therapy Cause Significant Changes to the Vitreous Proteome in Patients with Wet AMD** Bert Glaser

9:06 a.m.
**Intravitreal bevacizumab for the treatment of patients with low-vision due to neovascular AMD** Francesco Bandello

9:14 a.m.
**RPE atrophy in patients with exudative AMD undergoing anti-VEGF therapy** Noemi Lois

9:22 a.m.
**Occurrence Of Macular Haematoma After Intravitreal Injections Of Ranibizumab In Exudative Age-Related Macular Degeneration** Gisele Soubrane

9:30 a.m.
**A new grading system for RPE tears to assess the long-term prognosis with and without continued antiVEGF therapy** David Sarraf

9:38 a.m.
**Triple Therapy for Subfoveal Classic Choroidal Neovascularization (CNV) in Age-Related Macular Degeneration (ARMD)** R. Olk

9:46 a.m.
**Award: Young Investigator**
Recipient: K. Bailey Freund
Presenter: Alexander Brucker

10:18 a.m. *BREAK*
Session V: Diabetes II

Chair: David Brown
Moderator: Andreas Lauer

10:38 a.m.
Expanded 2-year Follow-up of a Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for DME  Michael Elman

10:46 a.m.
Ranibizumab or triamcinolone with focal/grid laser for eyes with diabetic macular edema requiring panretinal photocoagulation. Alexander Brucker

10:54 a.m.
Cost-Effectiveness Analysis of the DRCR Network Protocol I Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema  Rajendra Apte

11:02 a.m.
Frequency of Intraocular Pressure Increase within Days After Intravitreal Triamcinolone Injections in the Diabetic Retinopathy Clinical Research Network  Andreas Lauer

11:10 a.m.
(fluocinolone acetonide intravitreal insert for macular edema) Studies: Month 36 Results  David Brown

Session VI: Miscellaneous

Chair: Michael Marmor
Moderator: Michel Farah

11:18 a.m.
Understanding and Reporting Visual Acuity Measurements in Publications of Clinical Research in Retina  Susan Bressler

11:26 a.m.
Near visual acuity in patients with macular disease: Performance with printed and electronic displays  Mark Blumenkranz

11:34 a.m.
Low-Flow Lesion (LFL): A Distinct Subtype of Choroidal Neovascularization?  Rogerio Costa

11:42 a.m.
Lesion Size and Visual Prognosis of Polypoidal Choroidal Vasculopathy  Akitaka Tsujikawa

11:50 a.m.
Near-Infrared Autofluorescence in Patients with Idiopathic Submacular Choroidal Neovascularization  Tomohiro Iida

11:58 a.m.
Quantitative assessment of the 103-hexagon multifocal electroretinogram in detection of hydroxychloroquine retinal toxicity  Dennis Han
12:06 p.m.  
**Comparison of Diagnostic Tests in Hydroxychloroquine Toxicity**  Michael Marmor  

12:14 p.m.  
**Estimation of visualization of vital dyes used for macular surgery by luminance contrast**  Kazuaki Kadonosono  

12:22 p.m.  
**Evaluation of novel vital dyes for vitreoretinal surgery**  Michel Farah  

12:30 p.m.  
**Presentation of the Arnall Patz Award**  
Recipient: Leonidas Zografos  
Presenter: Evangelos Gragoudas  

12:38 p.m.  
**Paul Henkind Memorial Lecture and Award Presentation**  
Recipient: Joan Miller  
Presenter: Julia Haller  

1:02 p.m.  
End of Session  

---  

**SATURDAY, March 12, 2011**  
**Session VII: Pediatrics/Tumors**  
Chair: Evan Gragoudas  
Moderator: Jerry Shields  

7:30 a.m.  
**ROP Screening: Mitigating Malpractice Risk and Maximizing Efficient Use of Physician Resources**  
Antonio Capone, Jr.  

7:38 a.m.  
**A Case-Control Study of Bevacizumab for Coats Disease in Children**  G. Baker Hubbard, III  

7:46 a.m.  
**Intra-arterial chemotherapy for advanced retinoblastoma. The good news and the bad news.**  Carol Shields  

7:54 a.m.  
**GEP Class and Cytopathologic Category of Uveal Melanocytic Tumors Cells in 154 Cases**  James Augsburger  

8:02 a.m.  
**Ranibizumab in Combination with Proton Beam Irradiation for Choroidal Melanoma: One-Year Results**  Ivana Kim
8:10 a.m.  
**Metastatic Uveal Melanoma- Targeted molecules may be the answer**  
David Abramson

8:18 a.m.  
**PARANEOPlastic Bilateral Diffuse Uveal Melanocytic Proliferation** is caused by a factor found in the IgG fraction of serum  
Jose Pulido

8:26 a.m.  
**“Wide field (150°) angiography in Melanocytic Tumors before and after irradiation treatment”**  
Leonidas Zografos

8:34 a.m.  
**Radiation Dose and Optic Nerve Damage**  
Evangelos Gragoudas

8:42 a.m.  
**The expanding spectrum of retina vasoproliferative tumors**  
Jerry Shields

8:50 a.m.  
**Session VIII: Inflammation/Endophthalmitis/Retinal Degenerations**  
Chair: Edwin Stone  
Moderator: Henry Kaplan

8:58 a.m.  
**Focal Retinal Phlebitis**  
Lawrence Yannuzzi

9:06 a.m.  
**Endogenous Fungal Endophthalmitis: Causative organisms, management strategies and visual acuity outcomes**  
Thomas Albini

9:14 a.m.  
**Ophthalmic Antibiotics and Antimicrobial Resistance: A Randomized, Controlled Study of Patients Undergoing Intravitreal Injections**  
Stephen Kim

9:22 a.m.  
**Trusopt For Treatment of Macular Edema in Patients With Hereditary Retinal Diseases**  
Gerald Fishman

9:30 a.m.  
**Longitudinal assessment of parafoveal rings of high density fundus autofluorescence in retinitis pigmentosa.**  
Anthony Robson

9:38 a.m.  
**Phenotypic variability in autosomal recessive bestrophinopathy (ARB)**  
Graham Holder

9:46 a.m.  
**Photoreceptor Regeneration in a Swine Model of Retinal Damage**  
Henry Kaplan

9:54 a.m.
Use of patient specific iPSCs to model retinal degenerative disease  Edwin Stone

10:02 a.m.  Break

**Session IX: Vitreomacular Traction/Surgery**

Chair: Nancy Holekamp  Moderator: J. Fernando Arevalo

10:23 a.m.
A single injection of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (sVMA): Results of the Phase III MIVI-TRUST Program  Julia Haller

10:31 a.m.
**Time domain OCT vs Spectral Domain OCT to Evaluate Vitreomacular Adhesion, Macular Hole, and ERM in a Prospective Randomized Vitreous Pharmacolysis Trial**  Glenn Jaffe

10:39 a.m.
**Morphology of surgical ILM-specimens in macular hole**  Anselm Kampik

10:47 a.m.
**Swelling of the Arcuate Retinal Nerve Fiber Layer after Internal Limiting Membrane Peeling for Idiopathic Macular Hole and Epiretinal Membrane Removal**  Antonio Ciardella

10:55 a.m.
**Minimalist Pars Plana Vitrectomy For Repair Of Primary Rhegmatogenous Retinal Detachment**  Mark Johnson

11:03 a.m.
**Cauterization For Leaking Sclerotomies After Small-gauge Transconjunctival Pars Plana Vitrectomy**  Francesco Boscia

11:11 a.m.
**Rhegmatogenous Retinal Detachment after Laser-assisted In Situ Keratomileusis (LASIK) for Myopia of up to -10 Diopters: Ten years of Follow-up**  J. Fernando Arevalo

11:19 a.m.
**Why Vitrectomy Causes Glaucoma**  Nancy Holekamp

**Session X: Basic Science**

Chair: Timothy Olsen  Moderator: Elizabeth Hartnett

11:27 a.m.
**Identification of Small Molecule Therapeutics for ARMD**  Shalesh Kaushal
11:35 a.m.
Expression of Chemokine Receptors in Sub-Populations of White Blood Cell from Patients with Age-related Macular Degeneration Itay Chowers

11:43 a.m.
Identification of Rational Therapeutic Targets in Retinal Angiogenesis Franco Recchia

11:51 a.m.
Control Sustained Release from Biodegradable Thermo-Responsive Hydrogel William Mieler

11:59 a.m.
Novel delivery platform for dexamethasone sodium phosphate via PLGA nanospheres encapsulated within thermo-responsive hydrogel Jennifer Kang-Mieler

12:07 p.m.
The Role of Rap1 GTPase in Reducing CNV in Models of Neovascular AMD Mary Elizabeth Hartnett

12:15 p.m.
Regression of Surgically Induced Choroidal Neovascularization in the Porcine Model Timothy Olsen

12:23 p.m.
Targeting CC Chemokines in Diabetic Retinopathy Arup Das

12:31 p.m.: End of Session and Meeting